Real-life study in diabetic macular edema treated with dexamethasone implant: The reldex study

Retina

Volumn 37, Issue 4, 2017, Pages 753-760

  Malcles, Ariane ^a   Dot, Corinne ^b,c   Voirin, Nicolas ^a   Agard, Emilie ^b,c   Vie, Anne Laure ^a   Bellocq, David ^a   Denis, Philippe ^a   Kodjikian, Laurent ^a  

^a CROIX ROUSSE HOSPITAL   (France)

^b HIA Desgenettes   (France)

^c French Military Health Service Academy   (France)

Author keywords

Central macular thickness; Corticosteroids; Dexamethasone implant; Diabetic macular edema; Diabetic retinopathy; Ozurdex

Indexed keywords

DEXAMETHASONE; HEMOGLOBIN A1C; ANTIINFLAMMATORY AGENT; DELAYED RELEASE FORMULATION; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CASE STUDY; CENTRAL MACULAR THICKNESS; CLINICAL PRACTICE; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; PATIENT SAFETY; PHACOEMULSIFICATION; RETINA NEOVASCULARIZATION; RETREATMENT; RETROSPECTIVE STUDY; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; VERY ELDERLY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 85017390601     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001234     Document Type: Article

References (19)

1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-1474.
2. Early Treatment of Diabetic Retinopathy Study Group. Photocoagulation for macular edema. Early treatment diabetic retinopathy study report number Arch Ophthalmol 1985;103:1796-1806.
3. Cheung N, Wong IY, Wong TY. Ocular anti- VEGF therapy for diabetic retinopathy: over-view of clinical efficacy and evolving applications. Diabetes Care 2014;37:900-905.
4. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
5. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-1444.
6. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
7. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
8. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-1914.
9. Fraser-Bell S, Lim LL, Campain A, et al. Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). Ophthalmology 2016;123:1399-401.
10. Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M. Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema. Ophthalmologica 2015;233:176-185.
11. Guigou S, Pommier S, Meyer F, et al. Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica 2015;233:169-175.
12. Bonnin S, Dupas B, Sanharawi ME, et al. Efficacy of dexamethasone intravitreal implant for the treatment of diabetic macular edema. Eur J Ophthalmol 2015;25:448-453.
13. Dutra Medeiros M, Postorino M, Navarro R, et al. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2014;231:141-146.
14. Bansal P, Gupta V, Gupta A, et al. Efficacy of Ozurdex implant in recalcitrant diabetic macular edema-a single-center experience. Int Ophthalmol 2016;36:207-216.
15. Totan Y, Güler E, Güraǧaç FB. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res 2016;41:107-113.
16. Lam WC, Albiani DA, Yoganathan P, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 2015;9:1255-1268.
17. Zhioua I, Semoun O, Lalloum F, Souied EH. Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema. Retina 2015;35:1429-1435.
18. Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312-2318.
19. Campochiaro PA, Braown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-2132.